Research programme: antibacterials - Hawon
Alternative Names: KJO 18; KJO 26; Research programme: carbapenems - HawonLatest Information Update: 26 Apr 2007
At a glance
- Originator Hawon Pharmaceutical
- Class
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 26 Apr 2007 No development reported - Preclinical for Bacterial infections in South Korea (unspecified route)
- 26 Sep 2003 Preclinical trials in Bacterial infections in South Korea (unspecified route)